0001885444 false 0001885444 2023-07-19 2023-07-19 0001885444 KNSW:UnitsEachConsistingOfOneShareOfClassCommonStockAndOnehalfOfOneRedeemablePublicWarrantMember 2023-07-19 2023-07-19 0001885444 KNSW:ClassCommonStockParValue0.0001PerShareMember 2023-07-19 2023-07-19 0001885444 KNSW:PublicWarrantsEachWholePublicWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2023-07-19 2023-07-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549







Date of Report (Date of earliest event reported): July 19, 2023


KnightSwan Acquisition Corporation

(Exact name of registrant as specified in its charter)


Delaware 001-41238 87-2165133
(State or other jurisdiction
of incorporation)
File Number)
(I.R.S. Employer
Identification No.)


99 Wall Street, Suite 460

New York, New York

(Address of principal executive offices) (Zip Code)


(301) 613-8632

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered

Units, each consisting of one share of Class A common stock and one-half of one redeemable public warrant



New York Stock Exchange

Class A Common Stock, par value $0.0001 per share   KNSW  

New York Stock Exchange

Public warrants, each whole public warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share   KNSW WS  

New York Stock Exchange


Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 







Item 8.01.Other Items.

In connection with the special meeting called by the Company (the “Special Meeting”) to approve, among other things, an extension of time for KnightSwan Acquisition Corporation (the “Company”) to consummate an initial business combination (the “Extension Amendment Proposal”) from July 25, 2023 to July 25, 2024, or such earlier date as determined by the board of directors of the Company in its sole and absolute discretion (the “Extension”), shareholders holding an aggregate of 18,355,353 of the Company’s Class A ordinary shares exercised their right to redeem their shares prior to the redemption deadline on July 18, 2023. Following the withdrawals from the trust account in connection with such redemptions, it is expected that approximately $49,183,956 will remain in the trust account (assuming a redemption amount of approximately $10.55 per share).

Additionally, KnightSwan Sponsor LLC (the “Sponsor”), the sponsor of the Company, and the Company entered into non-redemption agreements (the “Non-Redemption Agreements”) with unaffiliated third-party investors (the “Investors”), including in the form attached hereto as Exhibit 10.1. Pursuant to the Non-Redemption Agreements, the Investors agreed not to redeem an aggregate of 4,000,000 Class A ordinary shares of the Company (the “Non-Redeemed Shares”) in connection with the Special Meeting. In exchange for the foregoing commitments not to redeem such shares, the Sponsor has agreed to transfer to the Investors an aggregate of 1,332,000 Class B ordinary shares of the Company held by the Sponsor immediately following consummation of an initial business combination if the Investors continue to hold such Non-Redeemed Shares through the Special Meeting. The Non-Redemption Agreements are not expected to increase the likelihood that the Extension Amendment Proposal is approved by shareholders but will increase the amount of funds that remain in the Company’s trust account following the Special Meeting. 

The foregoing summary of the Non-Redemption Agreements does not purport to be complete and is qualified in its entirety by reference to the form of Non-Redemption Agreement attached hereto as Exhibit 10.1 and incorporated herein by reference.

Cautionary Note Regarding Forward-Looking Statements

This current report includes, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this current report are forward-looking statements. When used in this current report, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to the Company or the Company’s management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the SEC. All subsequent written or oral forward-looking statements attributable to the Company or persons acting on the Company’s behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement and final prospectus relating to the Company’s initial public offering filed with the SEC. Copies are available on the SEC’s website at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by applicable law.

No Offer or Solicitation

This Current Report shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities. This communication shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.



Additional Information and Where to Find It

Information regarding how to attend the Company’s special meeting and vote is available in the Company's proxy statement, filed with the SEC on July 6, 2023 (the “Definitive Proxy Statement”). The Company urges investors, shareholders and other interested persons to read the Definitive Proxy Statement as well as other documents filed by the Company with the SEC, because these documents will contain important information about the Company and the Extension Amendment Proposal. Shareholders may obtain copies of the Definitive Proxy Statement, without charge, at the SEC’s website at www.sec.gov or by directing a request to the Company’s proxy solicitor, MacKenzie Partners, Inc, at 1407 Broadway - 27th Floor, New York, New York 10018, Toll-Free (800) 322-2885, Email: proxy@mackenziepartners.com.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits


  Description of Exhibits
10.1   Form of Non-Redemption Agreement
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)









Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.